

## INDEX

---

Note: page numbers in *italic* typeface indicate figures. Page numbers followed by a “t” indicate tables.  
Abbreviations are for terms listed on pages 135-137.

- Acetaminophen/tramadol in fibromyalgia, 95, 96
- Acupuncture, 101t, 106-107
- Adverse events
  - pooled data: treatment-emergent adverse events reported by >5% of patients in the duloxetine group and twice the rate of placebo, 82, 87
  - in pooled trials with pregabalin, 78, 80–81
- Aerobic exercise guidelines in fibromyalgia, 100, 103t
- American College of Rheumatology diagnostic criteria for fibromyalgia, 13, 18-25, 19
- Amitriptyline, 84-85, 91t, 92
  - combination treatment of fibromyalgia with fluoxetine and amitriptyline, 89, 93
  - initial prescription for, 120
- Analgesic activity, alterations in descending, 57, 58t
- Analgesics used in fibromyalgia trials, 71t
- Antidepressants
  - used in fibromyalgia therapy, 121
  - used in fibromyalgia trials, 71t
- Antiepileptics used in fibromyalgia trials, 71t
- Anti-inflammatory medications, 92, 94t
- Anxiety disorders
  - co-occurrence with fibromyalgia, 41, 43t, 114
  - and duloxetine, 82
- Autonomic dysfunction, 63
  
- Balneotherapy (medicinal bathing), 101t, 106
- Bipolar disorder, 44
- Brain
  - accelerated gray matter loss in fibromyalgia, 59, 62–63
  - brain regional blood flow response to pain in fibromyalgia vs controls, 58, 59, 60–61
  - neuroimaging in fibromyalgia, 59, 61t
  - neurostimulation, transcranial direct current stimulation (tDCS), 101t, 106, 109
  - transcranial magnetic stimulation (rTMS), 109
- Brief Pain Inventory (BPI), 78, 79, 82

Cardiovascular exercise, 99, 100-103  
 Carisoprodol used in fibromyalgia trials, 71t  
 Central nervous system  
   active medications used in fibromyalgia, Rationale for, 70t  
   pain dysregulation, 53, 54t, 57-59, 58. See also *Pain*.  
 Chemical sensitivity, multiple (MCS), 32, 36  
 Chiropractic therapy, 107  
 Chlorimipramine, 92  
 Chronic fatigue  
   in the general population, 32  
   recommendations for the evaluation and classification of  
     unexplained chronic fatigue, 33, 34, 35  
 Chronic fatigue syndrome  
   diagnostic criteria, 31, 33  
   history of, 33  
 Citalopram, 89, 92  
 Clinical diagnosis of fibromyalgia, 17-30  
 Cognitive behavior therapy  
   and education in fibromyalgia, 106, 107  
   goals and methods of, 104, 105t  
   improvements with, vs standard care over 12 months, 105  
   as treatment, 99, 100t, 101t, 104-106, 109t  
 Cognitive problems in fibromyalgia, 22, 46t, 47, 47t  
 Cyclobenzaprine used in fibromyalgia trials, 71t  
 Cytokines, 63  
  
 Depression, 32, 36, 44t  
   comorbid with fibromyalgia, 41, 42, 43, 114  
   and duloxetine, 82  
   strategies to achieve improvement in comorbid major  
     depression and fibromyalgia, 125t  
 Dextromethorphan, 93, 94  
 Disability, 131-132, 132t  
 Dolorimeter, 20  
 Duloxetine, 69  
    $\geq 50\%$  improvement in average pain scores with duloxetine  
     in 3- and 6-month treatment phases, 82, 88  
   clinical trials in fibromyalgia, 79, 83t  
   improvement in average pain severity with duloxetine, 79, 84  
   improvement in function (FIQ) with duloxetine, 79, 85  
   initial prescription for, 120  
   pooled data: duloxetine efficacy in fibromyalgia patients  
     with and without major depressive disorder, 82, 86

## Duloxetine (*continued*)

pooled data: treatment-emergent adverse events reported by  
 >5% of patients in the duloxetine group and twice the  
 rate of placebo, 82, 87

## Education

benefits of exercise enhanced by self-management  
 education, 106, 108  
 cognitive behavior therapy and education in fibromyalgia,  
 106, 107  
 disability avoidance, 131-132, 132t  
 explaining the typical outcome in fibromyalgia, 118t  
 patient and family education, 114-119, 116t  
 spontaneous remission of fibromyalgia, 119, 131  
 structuring group fibromyalgia education, 116t  
 web sites with fibromyalgia information, 118

## Electrotherapy, 107

EMG biofeedback, 101t, 106

Epstein-Barr virus, 33

Etiologic links, possible, between mood disorders and  
 fibromyalgia, 51t

## European Union League Against Rheumatism (EULAR)

conclusions regarding nonmedicinal therapy, 109, 109t  
 recommendations for management of fibromyalgia, 126t

## Exercise

aerobic exercise guidelines for fibromyalgia patients, 100,  
 102, 103, 103t

aerobic exercise vs untreated controls: mean differences,  
 100, 102, 106, 107

benefits of exercise enhanced by self-management  
 education, 106, 108

benefits of exercise to the fibromyalgia patient, 99-112

cardiovascular exercise, 99, 100-103

exercise rationale in fibromyalgia, 99, 101t

improvements with aerobic exercise vs  
 nonexercise controls, 102

prescription for, 103-104

strengthening exercise vs controls: mean difference, 100, 103

water exercise, water aerobics, deep water walking, 100, 117

## Fibromyalgia

accurate diagnosis and symptom assessment, 113-115

analgesic activity, alterations in descending, 57, 58t

association with mood, cognitive, and

sleep disturbances, 41-52

## Fibromyalgia (*continued*)

- central nervous system active medications, rationale for the use of in fibromyalgia, 70t
- cognitive problems in, 46t
- comprehensive management plan, 113-128
- concurrent illnesses, medically unexplained, 31-40, 32t
- controversies in the management of, 129-134
- co-occurrence with anxiety and mood disorders, 43t
- definitions, causes, and prevalence of, 9-16, 10t, 11t
- diagnosis of, 17-30
  - American College of Rheumatology diagnostic criteria, 19
  - common descriptions of symptoms by patients, 17-18t
  - diagnostic questions to ask patients, 17
  - diagnostic work-up, 26
  - differential diagnosis of, 25-28, 27t
  - fibromyalgia: a constellation of symptoms, 25
  - fibromyalgia diagnosis improves patient satisfaction, 119
  - fibromyalgia symptom evaluation, 24
  - impact on National Health Service resources and expenses (in British pounds) of making a diagnosis of fibromyalgia syndrome, 119, 121, 122-123
  - laboratory evaluation, 28t
  - positive impact of fibromyalgia diagnosis in clinical practice, 119, 120
  - routine tests for, 27, 28t
  - Structured Interview, 22, 24t
  - the tender-point examination, 20-21
- and disability, 131-132
- efficacy of various medications in
  - initial fibromyalgia trials, 84, 92
- EULAR recommendations for management of, 126t
- evidence-based management of, 125t
- explaining the typical outcome in, 118t
- functional disorders that often overlap with, 36t
- genetic predisposition for, 53-57, 56t
- historical perspective, 11-13
- initial description of, 12
- initial treatment of, 113, 114, 120, 124
- is fibromyalgia a medical or psychiatric illness?, 41, 129, 130t
- medically unexplained illnesses concurrent with, 32t
- medication choices and individualizing therapy, 120-127
- medicines used in fibromyalgia trials, 71t
- and mood disorders, 43t
- mood disorders and fibromyalgia: possible etiologic links, 51t

## Fibromyalgia (*continued*)

- neuroimaging in, 59, 61t
- nonpharmacologic management of, 99-112
- outcome and disability in, 131, 132t
- pathophysiologic pathways, 53, 54t
- patient descriptions of, 18t
- possible onset triggers, 57
- spontaneous remission, 119, 131
- subgroups of fibromyalgia patients, identifying may help individualize treatment of, 126, 127t
- symptoms of, 17-25
- when to think of fibromyalgia, 11t
- who gets fibromyalgia?, 10t
- who should treat fibromyalgia?, 130-131, 130t
- Fibromyalgia Impact Questionnaire (FIQ), 24, 71, 78, 79, 85, 94t, 108
- Fibromyalgia syndrome, multidisciplinary treatment of, 117, 117t, 123
- Fluoxetine, 89, 92, 93
- Fluvoxamine, 89
- Gabapentin, 69, 72
  - 30% reduction on average pain severity score with gabapentin, 78-79, 82
  - used in fibromyalgia trials, 71t
- Gamma hydroxybutyrate/sodium oxybate (sodium salt of GHB), 94t
- Genetics of fibromyalgia, 54, 56, 56t
- Glutamate, higher levels associated with increased fibromyalgia pain, 59, 62, 63, 70, 72
- Gowers, Sir William, 12
- Growth hormone (GH), 95
- Headaches, 37, 42
- Hypnotherapy, 101t, 106
- Hypothalamic-pituitary-adrenal (HPA) axis, 59, 61, 63, 64, 65
- Illnesses, medically unexplained, concurrent with
  - fibromyalgia, 31-40, 32t
- Interstitial cystitis, 37
- Irritable bowel syndrome (IBS), 36, 42
- Kahlo, Frida, self portrait of, 1916, 13, 14
- Ketamine, 93, 94

Magnetic resonance spectroscopy, 53, 55  
Manningham, Sir Richard, 11, 33  
Maprotiline, 92  
Massage therapy, 107, 109  
Medications  
  antidepressants used in fibromyalgia trials, 71t  
  anti-inflammatory medications, 92, 94t  
  central nervous system active medications, rationale for  
    the use of in fibromyalgia, 70t  
  chlorimipramine, 92  
  combination treatment  
    after initial therapy, 121  
    with fluoxetine and amitriptyline, 89, 93  
  duloxetine: clinical trials in fibromyalgia, 79, 83t  
  efficacy of various medications in initial fibromyalgia trials,  
    84, 92  
  fluvoxamine, 89  
  further medication and nonpharmacologic treatment of  
    fibromyalgia: often with specialists' input, 121, 124  
  initial medication and nonpharmacologic treatment of  
    fibromyalgia, 120, 124  
  initial pregabalin in fibromyalgia study design, 70, 73  
  maprotiline, 92  
  medication choices and individualizing therapy, 120-127  
  medicines used in fibromyalgia trials, 71t  
  milnacipran, 79, 83-84, 89, 90  
  nonbenzodiazepine sedatives, 89, 94t  
  NSAIDs used in fibromyalgia trials, 71t  
  pregabalin and gabapentin, 70, 72  
  sedatives and hypnotics, 89, 94t  
  SSRIs used in fibromyalgia trials, 71t, 93  
  tramadol/acetaminophen, 95, 96  
  tricyclics, 84, 85, 91t  
  venlafaxine: clinical trials in fibromyalgia, 79, 83t  
Meditation, relaxation, and stress management techniques, 107  
Mental problems  
  bipolar disorder, 44  
  comorbid with fibromyalgia, 44, 44  
  is fibromyalgia a medical or psychiatric illness?, 129, 130t  
  psychiatric disorders in fibromyalgia patients, nonpatients,  
    and controls, 41, 44  
  psychiatric disorders in patients with regional and  
    widespread pain, 45t  
Methocarbamol used in fibromyalgia trials, 71t

Milnacipran, 79  
  efficacy of milnacipran in initial fibromyalgia randomized  
    clinical trial, 83, 89  
  mean change in pain with milnacipran, 83-84, 90  
Mood disorders  
  associated with fibromyalgia, 41, 42, 43t, 44t, 51t  
  and conditions comorbid with fibromyalgia, 31  
  evaluation and management of, need for, 114  
  and fibromyalgia, 43t, 44t  
  lifetime prevalence of, in relatives of 78 probands with  
    fibromyalgia and 40 probands with rheumatoid arthritis, 44t  
  overlap of mood disorders and functional illness of  
    population (%), 41, 42  
  possible etiologic links between mood disorders and  
    fibromyalgia, 51t  
Multiple chemical sensitivity (MCS), 32, 36  
Muscle  
  muscle relaxants used in fibromyalgia trials, 71t  
Muscle relaxants used in fibromyalgia trials, 71t  
Muscles  
  arousal disturbances with disruption of slow-wave (deep)  
    sleep caused muscular pain and fatigue and increased  
    sensitivity to pain, 48-50  
  no evidence of abnormal muscle metabolism in NMR  
    spectroscopy in fibromyalgia vs controls, 53, 55  
Myofascial pain vs fibromyalgia, 37t  
  
Neuroendocrine factors, interactions of, on pain, 66  
Neuroendocrine studies in fibromyalgia, 59, 64  
Neuroendocrine system and stress, 59-65, 66  
Neuroimaging in fibromyalgia, 59, 61t  
Neurostimulation of the brain, transcranial direct current  
  stimulation (tDCS), 101t, 106, 109  
N-methyl-D-aspartate (NMDA) receptor, 57  
Nonbenzodiazepine sedatives, 89, 94t  
Nonmedicinal therapy of fibromyalgia: EULAR conclusions  
  regarding, 109t  
Nonpharmacologic approach to fibromyalgia treatment, 100t  
Nonpharmacologic management of fibromyalgia, 99-112  
Nonpharmacologic strategies: evidence of efficacy, 101t  
NSAIDs used in fibromyalgia trials, 71t  
  
Opioids, opiates, 95

Pain. See also *Central nervous system: pain dysregulation*.  
≥50% improvement in average pain scores with duloxetine  
in 3- and 6-month treatment phases, 82, 88  
30% reduction on average pain severity score with  
gabapentin, 78, 82  
arousal disturbances with disruption of slow-wave (deep)  
sleep caused muscular pain, fatigue, and increased  
sensitivity to pain, 48–50  
brain regional blood flow response to pain in fibromyalgia vs  
controls, 59, 60–61  
Brief Pain Inventory (BPI), 78, 79, 82  
catechol-*O*-methyltransferase (COMT) genotype, 54, 56, 56t  
chronic widespread pain (CWP), 45, 45t, 65  
higher glutamate levels associated with increased  
fibromyalgia pain, 59, 62, 63  
improvement in average pain severity with duloxetine, 79, 84  
improvement with pregabalin in fibromyalgia, 71, 76  
mean change in pain with milnacipran, 84, 90  
mean pain scores: pregabalin in fibromyalgia, 75  
neuroendocrine factors, interactions of, on pain, 66  
*N*-methyl-*D*-aspartate (NMDA) receptor, 57  
odds of developing chronic widespread pain based on HPA  
function, 63, 65  
pain augmentation: wind-up, 57, 58  
pain augmentation disorder, 53, 54t  
pain diagram from a patient with fibromyalgia, 22, 23  
Patient Global Impression of Improvement (PGI-I), 79, 82  
regional and widespread, and psychiatric disorders, 45t  
Short-Form McGill Pain Questionnaire (SF-MPQ), 70  
TMJD incidence rates for COMT haplotypes and  
experimental pain groups, 54, 56  
wind up, 57, 58  
Parasympathetic activity, 65  
Paroxetine, 89, 93  
Pathophysiology, 53-68  
Patient Global Impression of Change (PGIC), 71, 77, 78  
Patient Global Impression of Improvement (PGI-I), 79, 82  
Patient subgroups, identification of, 126, 127t  
Polymyalgia rheumatica (PMR), 25, 26  
Pramipexole used in fibromyalgia trials, 71t, 94t  
Prednisone, 94t  
Pregabalin, 68-78, 80–81  
adverse events in pooled trials with pregabalin, 78, 80–81  
Demographic and Baseline Characteristics in  
First Pregabalin Trial, 74t

Pregabalin (*continued*)  
in fibromyalgia: patient global impression of change, 75  
and gabapentin, 70, 72  
initial pregabalin in fibromyalgia study design, 70, 73  
initial prescription for, 120  
mean pain scores: pregabalin in fibromyalgia, 75  
pain improvement with pregabalin in fibromyalgia, 71, 76  
percentage improvement with various doses of pregabalin in  
fibromyalgia, 71, 76  
time to loss of therapeutic response to pregabalin vs  
placebo, 77  
two studies used to establish FDA approval, 70-78  
used in fibromyalgia trials, 71t  
Psychiatric disorders in patients with regional and  
widespread pain, 45t

Qigong, 107

Questionnaire: Short-Form McGill Pain Questionnaire  
(SF-MPQ), 70

Questions to ask patients, diagnostic, 17

Remission, spontaneous, of fibromyalgia, 119, 131

Rheumatologists as consultants, 130t, 131

Rome I and Rome II criteria, 36

S-adenosylmethionine, 92

Sedatives and hypnotics in fibromyalgia, 71t, 89, 94t

Short-Form McGill Pain Questionnaire (SF-MPQ), 70

Sjögren's syndrome, 10, 22, 25, 26, 27

Sleep

arousal disturbances with disruption of slow-wave (deep)  
sleep caused muscular pain and fatigue and increased  
sensitivity to pain, 47, 48–50

referral of patient to a sleep laboratory, 114

SNRIs used in fibromyalgia trials, 71t

Sodium oxybate used in fibromyalgia trials, 71t

Somatization disorder, 45, 45t, 46, 131

Specialists, referral of patients to, 121, 123

SSRIs used in fibromyalgia trials, 71t, 85, 89, 93

Stockman, Ralph, 12

Stress

chronic, 51, 51t

and the neuroendocrine system, 59-65, 66

Stress management techniques, meditation, and relaxation, 107

Substance P, 70, 72

Sympathetic hyperactivity, 65

Symptom

evaluation of fibromyalgia symptoms, 22, 24

fibromyalgia: a constellation of symptoms, 21, 22, 25, 25

Tai chi, 107

Task switching and rule complexity, effects of, in

fibromyalgia vs healthy controls, 47

TCAs used in fibromyalgia trials, 71t

Tender points, 13, 18-25

distinguished from trigger points, 37

the tender-point examination, 19, 20-21

Tizanidine used in fibromyalgia trials, 71t

TMJ syndrome, also called TMD or TMJD, 22, 36t, 38

TMJD incidence rates for COMT haplotypes and

experimental pain groups, 54, 56

Tramadol, 71t, 93, 94, 121

Tramadol/acetaminophen in fibromyalgia, 94-95, 96

Trauma: relationship of trauma onset of fibromyalgia with

disability application, 115

Trazodone used in fibromyalgia trials, 71t

Treatment

effective management in lieu of a cure, 133

individualized according to patient subgroups, 126, 127t

recommendations based on evidence from clinical trials,

125, 125t

who should treat fibromyalgia?, 130-131, 130t

Tricyclic antidepressants, 84-85, 91t

Trigger points, distinguished from tender points, 37

Tropisetron, 94t

Ultrasound therapy, 107

Venlafaxine: clinical trials in fibromyalgia, 79, 83t

Visual Analog Scale (VAS), 70

Water exercise, water aerobics, deep water walking, 100, 117

Web sites with fibromyalgia information, 118

Wind up, 57, 58

Yoga, 107

Zolpidem, 71t, 89, 94t

Zopiclone, 71t, 89, 94t